Journal article icon

Journal article

Divergent Brain Network Activity in Asymptomatic C9orf72 and SOD1 Variant Carriers Compared With Established Amyotrophic Lateral Sclerosis

Abstract:
Understanding the presymptomatic biology in those at high risk of developing amyotrophic lateral sclerosis (ALS) is essential for the development of preventative therapeutic interventions. Approximately 10% of ALS is associated with a C9orf72 expansion or pathogenic variants in SOD1. Magnetoencephalography (MEG), combined with machine learning algorithms, can model brain network dynamics in such at‐risk populations to develop pathogenic biomarkers. Individuals with symptomatic ALS (symALS, n = 61), asymptomatic C9orf72 carriers (aC9, n = 16), or pathological SOD1 carriers (aSOD, n = 12), and healthy controls (n = 84) underwent resting‐state MEG recordings. Extracted metrics included regional oscillatory power, connectivity, and spectral shape. ‘DyNeMo’ was trained to identify six functional dynamic brain networks. Metrics were compared between groups. A classifier was trained to distinguish asymptomatic gene carriers from controls. Compared to controls, beta frequency power was decreased in both symALS and aC9 groups. The aC9 group showed a marked slowing of frontal oscillatory activity, while the aSOD group showed a marked acceleration. Dynamic network coactivation was dramatically disrupted in aC9, more than in both symALS and aSOD. The classifier accurately distinguished genetically at‐risk groups from controls (receiver‐operator‐characteristic area‐under‐curve 0.89). The cerebral network dynamics of aC9 are markedly different from both aSOD and symALS, supporting the concept of profoundly different upstream pathways in SOD1 ALS, sparing wider cortical pathology when compared to C9orf72 ALS. aC9 changes may reflect chronic adaptive changes relating to neurodevelopmental factors or underpin aspects of system vulnerability that define penetrance variability. MEG metrics might provide important biomarkers of prevention therapy efficacy and phenoconversion in at‐risk populations.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1002/hbm.70345

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-4848-6156
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-0888-1207
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-0774-4366
More by this author
Institution:
University of Oxford
Role:
Author


More from this funder
Funder identifier:
https://ror.org/00mwp5989
More from this funder
Funder identifier:
https://ror.org/01cwqze88
More from this funder
Funder identifier:
https://ror.org/01frxsf98
More from this funder
Funder identifier:
https://ror.org/02gq0fg61


Publisher:
Wiley
Journal:
Human Brain Mapping More from this journal
Volume:
46
Issue:
14
Article number:
e70345
Publication date:
2025-10-03
Acceptance date:
2025-08-27
DOI:
EISSN:
1097-0193
ISSN:
1065-9471


Language:
English
Keywords:
Pubs id:
2297275
Local pid:
pubs:2297275
Source identifiers:
3339489
Deposit date:
2025-10-03
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP